Startseite Serum N-glycan fingerprint nomogram predicts liver fibrosis: a multicenter study
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Serum N-glycan fingerprint nomogram predicts liver fibrosis: a multicenter study

  • Chenjun Huang ORCID logo , Lijuan Liu , Hao Wang , Meng Fang , Huijuan Feng , Ya Li , Mengmeng Wang , Lin Tong , Xiao Xiao , Ziyi Wang , Xuewen Xu , Yutong He und Chunfang Gao EMAIL logo
Veröffentlicht/Copyright: 8. Januar 2021
Veröffentlichen auch Sie bei De Gruyter Brill
Manuskript einreichen Informationen für Autor*innen
Clinical Chemistry and Laboratory Medicine (CCLM)
Aus der Zeitschrift Clinical Chemistry and Laboratory Medicine (CCLM) Band 59 Heft 6

Abstract

Objectives

Liver cirrhosis (LC) is the end-stage of fibrosis in chronic liver diseases, non-invasive early detection of liver fibrosis (LF) is particularly essential for therapeutic decision. Aberrant glycosylation of glycoproteins has been demonstrated to be closely related to liver abnormalities.

Methods

This study was designed to enroll a total of 1,565 participants with LC/LF, chronic hepatitis virus (CHB) and healthy controls. Fibrosis was confirmed by liver biopsy. Using capillary electrophoresis N-glycan fingerprint (NGFP) analysis, we developed a nomogram algorithm (FIB-G) to discriminate LC from non-cirrhotic subjects.

Results

The FIB-G demonstrated good diagnostic performances in identifying LC with the area under the curve (AUC) 0.895 (95%CI: 0.857–0.915). Furthermore, the diagnostic efficiencies of FIB-G were superior to that of log (P2/P8), procollagen III N-terminal (PIIINP), type IV collage (IV-C), laminin (LN), hyaluronic acid (HA), aspartate transaminase to platelets ratio index (APRI), and FIB-4 when detecting significant fibrosis (S0–1 vs. S2–4, AUC: 0.787, 95%CI: 0.701–0.873), severe fibrosis (S0–2 vs. S3–4, AUC: 0.844, 95%CI: 0.763–0.924), and LC (S0–3 vs. S4, AUC: 0.773, 95%CI: 0.667–0.880). Besides, changes of FIB-G were associated well with the regression of fibrosis and liver function Child–Pugh classification.

Conclusions

FIB-G is an accurate multivariant N-glycomic algorithm for LC prediction and fibrosis progression/regression monitoring. The high throughput feasible NGFP using only 2 μL of serum could help physicians make the more precise non-invasive staging of LF or cirrhosis and reduce the need for invasive liver biopsy.

Keywords: liver cirrhosis; liver fibrosis; N-glycan; nomogram; prediction
Corresponding author: Chunfang Gao, MD, PhD, Department of Laboratory Medicine, Shanghai Eastern Hepatobiliary Surgery Hospital, 225 Changhai Road, Shanghai, 200438, P.R. China, Phone: +86 21 81875130, Fax: +86 21 65562400, E-mail:
Chenjun Huang, Lijuan Liu and Hao Wang contributed equally to this work.

Funding source: China National Key Projects for Infectious Disease

Award Identifier / Grant number: 2018ZX10302205-003

Funding source: Shanghai Science and Technology Commission

Award Identifier / Grant number: 17411960500

Award Identifier / Grant number: 17JC1404500

Acknowledgments

We are very grateful to Shanghai Jing’an District Central Hospital for providing liver fibrosis samples. We are grateful for Ms. Minfan Xu and Ms. Song Hong for the help of sample collection.

  1. Research funding: This work was supported by the China National Key Projects for Infectious Disease (2018ZX10302205-003), the Shanghai Science and Technology Commission (17411960500; 17JC1404500).

  2. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  3. Competing interests: All authors claim that there is no conflict of interest including a desire for financial gain, prominence, professional advancement or a successful outcome.

  4. Informed consent: Informed consent was obtained from all individuals included in this study.

  5. Ethical approval: The study was approved by the Institutional Review Boards at the leading study center. Informed consent was obtained from each participant.

References

1. El-Serag, HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012;142:1264–73.e1. https://doi.org/10.1053/j.gastro.2011.12.061.Suche in Google Scholar PubMed PubMed Central

2. Gassmann, P, Spieker, T, Haier, J, Schmidt, F, Mardin, WA, Senninger, N. Prognostic impact of underlying liver fibrosis and cirrhosis after curative resection of hepatocellular carcinoma. World J Surg 2010;34:2442–51. https://doi.org/10.1007/s00268-010-0655-5.Suche in Google Scholar PubMed

3. Schuppan, D, Ashfaq-Khan, M, Yang, AT, Kim, YO. Liver fibrosis: direct antifibrotic agents and targeted therapies. Matrix Biol 2018;68–69:435–51. https://doi.org/10.1016/j.matbio.2018.04.006.Suche in Google Scholar PubMed

4. EASL. EASL recommendations on treatment of hepatitis C 2016. J Hepatol 2017;66:153–94. https://doi.org/10.1016/j.jhep.2016.09.001.Suche in Google Scholar PubMed

5. Zeng, M-D, Lu, L-G, Mao, Y-M, Qiu, D-K, Li, J-Q, Wan, M-B, et al.. Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model. Hepatology 2005;42:1437–45. https://doi.org/10.1002/hep.20960.Suche in Google Scholar PubMed

6. Sharma, S, Khalili, K, Nguyen, GC. Non-invasive diagnosis of advanced fibrosis and cirrhosis. World J Gastroenterol 2014;20:16820–30. https://doi.org/10.3748/wjg.v20.i45.16820.Suche in Google Scholar PubMed PubMed Central

7. Afdhal, NH, Nunes, D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol 2004;99:1160–74. https://doi.org/10.1111/j.1572-0241.2004.30110.x.Suche in Google Scholar PubMed

8. Clerc, F, Reiding, KR, Jansen, BC, Kammeijer, GSM, Bondt, A, Wuhrer, M. Human plasma protein N-glycosylation. Glycoconj J 2016;33:309–43. https://doi.org/10.1007/s10719-015-9626-2.Suche in Google Scholar PubMed PubMed Central

9. Wang, M, Zhu, J, Lubman, DM, Gao, C. Aberrant glycosylation and cancer biomarker discovery: a promising and thorny journey. Clin Chem Lab Med 2019;57:407–16. https://doi.org/10.1515/cclm-2018-0379.Suche in Google Scholar PubMed PubMed Central

10. Lin, Z, Simeone, DM, Anderson, MA, Brand, RE, Xie, X, Shedden, KA, et al.. Mass spectrometric assay for analysis of haptoglobin fucosylation in pancreatic cancer. J Proteome Res 2011;10:2602–11. https://doi.org/10.1021/pr200102h.Suche in Google Scholar PubMed PubMed Central

11. Wang, M, Fang, M, Zhu, J, Feng, H, Warner, E, Yi, C, et al.. Serum N-glycans outperform CA19-9 in diagnosis of extrahepatic cholangiocarcinoma. Electrophoresis 2017;38:2749–56. https://doi.org/10.1002/elps.201700084.Suche in Google Scholar PubMed

12. Matsuda, A, Kuno, A, Nakagawa, T, Ikehara, Y, Irimura, T, Yamamoto, M, et al.. Lectin microarray-based sero-biomarker verification targeting aberrant O-linked glycosylation on mucin 1. Anal Chem 2015;87:7274–81. https://doi.org/10.1021/acs.analchem.5b01329.Suche in Google Scholar PubMed

13. Callewaert, N, Van Vlierberghe, H, Van Hecke, A, Laroy, W, Delanghe, J, Contreras, R. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med 2004;10:429–34. https://doi.org/10.1038/nm1006.Suche in Google Scholar PubMed

14. Gui, H-l, Gao, C-f, Wang, H, Liu, X-e, Xie, Q, Dewaele, S, et al.. Altered serum N-glycomics in chronic hepatitis B patients. Liver Int 2010;30:259–67. https://doi.org/10.1111/j.1478-3231.2009.02170.x.Suche in Google Scholar PubMed

15. Vanderschaeghe, D, Laroy, W, Sablon, E, Halfon, P, Van Hecke, A, Delanghe, J, et al.. GlycoFibroTest is a highly performant liver fibrosis biomarker derived from DNA sequencer-based serum protein glycomics. Mol Cell Proteomics 2009;8:986–94. https://doi.org/10.1074/mcp.m800470-mcp200.Suche in Google Scholar PubMed PubMed Central

16. Fang, M, Zhao, Y-P, Zhou, F-G, Lu, L-G, Qi, P, Wang, H, et al.. N-glycan based models improve diagnostic efficacies in hepatitis B virus-related hepatocellular carcinoma. Int J Canc 2010;127:148–59. https://doi.org/10.1002/ijc.25030.Suche in Google Scholar PubMed

17. Yang, T, Xing, H, Wang, G, Wang, N, Liu, M, Yan, C, et al.. A novel online calculator based on serum biomarkers to detect hepatocellular carcinoma among patients with hepatitis B. Clin Chem 2019;65:1543–53. https://doi.org/10.1373/clinchem.2019.308965.Suche in Google Scholar PubMed

18. Scheuer, PJ. The nomenclature of chronic hepatitis: time for a change. J Hepatol 1995;22:112–14. https://doi.org/10.1016/0168-8278(95)80269-x.Suche in Google Scholar PubMed

19. Ho, C-H, Chien, R-N, Cheng, P-N, Liu, J-H, Liu, C-K, Su, C-S, et al.. Aberrant serum immunoglobulin G glycosylation in chronic hepatitis B is associated with histological liver damage and reversible by antiviral therapy. J Infect Dis 2015;211:115–24. https://doi.org/10.1093/infdis/jiu388.Suche in Google Scholar PubMed

20. Vallet-Pichard, A, Mallet, V, Nalpas, B, Verkarre, V, Nalpas, A, Dhalluin-Venier, V, et al.. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007;46:32–6. https://doi.org/10.1002/hep.21669.Suche in Google Scholar PubMed

21. McPherson, S, Stewart, SF, Henderson, E, Burt, AD, Day, CP. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010;59:1265–9. https://doi.org/10.1136/gut.2010.216077.Suche in Google Scholar PubMed

22. Sterling, RK, Lissen, E, Clumeck, N, Sola, R, Correa, MC, Montaner, J, et al.. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006;43:1317–25. https://doi.org/10.1002/hep.21178.Suche in Google Scholar PubMed

23. Zhao, Y-P, Ruan, C-P, Wang, H, Hu, Z-Q, Fang, M, Gu, X, et al.. Identification and assessment of new biomarkers for colorectal cancer with serum N-glycan profiling. Cancer 2012;118:639–50. https://doi.org/10.1002/cncr.26342.Suche in Google Scholar PubMed

24. Fang, M, Dewaele, S, Zhao, Y-P, Stärkel, P, Vanhooren, V, Chen, Y-M, et al.. Serum N-glycome biomarker for monitoring development of DENA-induced hepatocellular carcinoma in rat. Mol Canc 2010;9:215. https://doi.org/10.1186/1476-4598-9-215.Suche in Google Scholar PubMed PubMed Central

25. Yang, XZ, Gen, AW, Xian, JC, Xiao, L. Diagnostic value of various noninvasive indexes in the diagnosis of chronic hepatic fibrosis. Eur Rev Med Pharmacol Sci 2018;22:479–85. https://doi.org/10.26355/eurrev_201801_14198.Suche in Google Scholar PubMed

26. Boursier, J, de Ledinghen, V, Leroy, V, Anty, R, Francque, S, Salmon, D, et al.. A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis. J Hepatol 2017;66:1158–65. https://doi.org/10.1016/j.jhep.2017.01.003.Suche in Google Scholar PubMed

27. Haghgoo, SM, Sharafi, H, Alavian, SM. Serum cytokines, adipokines and ferritin for non-invasive assessment of liver fibrosis in chronic liver disease: a systematic review. Clin Chem Lab Med 2019;57:577–610. https://doi.org/10.1515/cclm-2018-0357.Suche in Google Scholar PubMed

28. Zou, X, Zhu, M-Y, Yu, D-M, Li, W, Zhang, D-H, Lu, F-J, et al.. Serum WFA-M2BP levels for evaluation of early stages of liver fibrosis in patients with chronic hepatitis B virus infection. Liver Int 2017;37:35–44. https://doi.org/10.1111/liv.13188.Suche in Google Scholar PubMed

29. Morelle, W, Flahaut, C, Michalski, J-C, Louvet, A, Mathurin, P, Klein, A. Mass spectrometric approach for screening modifications of total serum N-glycome in human diseases: application to cirrhosis. Glycobiology 2006;16:281–93. https://doi.org/10.1093/glycob/cwj067.Suche in Google Scholar PubMed

30. Liu, X-E, Desmyter, L, Gao, C-F, Laroy, W, Dewaele, S, Vanhooren, V, et al.. N-glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus. Hepatology 2007;46:1426–35. https://doi.org/10.1002/hep.21855.Suche in Google Scholar PubMed

31. Ishibashi, K, Nishikawa, A, Hayashi, N, Kasahara, A, Sato, N, Fujii, S, et al.. N-acetylglucosaminyltransferase III in human serum, and liver and hepatoma tissues: increased activity in liver cirrhosis and hepatoma patients. Clin Chim Acta 1989;185:325–32. https://doi.org/10.1016/0009-8981(89)90223-4.Suche in Google Scholar PubMed

32. Gressner, OA, Gao, C. Monitoring fibrogenic progression in the liver. Clin Chim Acta 2014;433:111–22. https://doi.org/10.1016/j.cca.2014.02.021.Suche in Google Scholar PubMed

33. Friedman, SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000;275:2247–50. https://doi.org/10.1074/jbc.275.4.2247.Suche in Google Scholar PubMed

34. Ismail, MH, Pinzani, M. Reversal of liver fibrosis. Saudi J Gastroenterol 2009;15:72–9. https://doi.org/10.4103/1319-3767.45072.Suche in Google Scholar PubMed PubMed Central

35. EASL. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57:167–85. https://doi.org/10.1016/j.jhep.2012.02.010.Suche in Google Scholar PubMed

36. Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. The guidelines of prevention and treatment for chronic hepatitis B (2019 version). Zhonghua Gan Zang Bing Za Zhi (Chinese) 2019;27:938–61. https://doi.org/10.3760/cma.j.issn.1007-3418.2019.12.007.Suche in Google Scholar PubMed

37. Schiff, ER, Lee, SS, Chao, Y-C, Kew Yoon, S, Bessone, F, Wu, S-S, et al.. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol 2011;9:274–6. https://doi.org/10.1016/j.cgh.2010.11.040.Suche in Google Scholar PubMed

38. Lok, ASF, McMahon, BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661–2. https://doi.org/10.1002/hep.23190.Suche in Google Scholar PubMed

Supplementary Material

The online version of this article offers supplementary material (https://doi.org/10.1515/cclm-2020-1588).

Received: 2020-10-20
Accepted: 2020-12-11
Published Online: 2021-01-08
Published in Print: 2021-05-26

© 2020 Walter de Gruyter GmbH, Berlin/Boston

Artikel in diesem Heft

  1. Frontmatter
  2. Editorial
  3. COVID-19: which lessons have we learned?
  4. Review
  5. Global FT4 immunoassay standardization: an expert opinion review
  6. Mini Review
  7. Mechanism of bilirubin elimination in urine: insights and prospects for neonatal jaundice
  8. Opinion Paper
  9. Laboratory medicine in the COVID-19 era: six lessons for the future
  10. EFLM Paper
  11. How to meet ISO15189:2012 pre-analytical requirements in clinical laboratories? A consensus document by the EFLM WG-PRE
  12. General Clinical Chemistry and Laboratory Medicine
  13. External quality assessment of M-protein diagnostics: a realistic impression of the accuracy and precision of M-protein quantification
  14. Error simulation modeling to assess the effects of bias and precision on bilirubin measurements used to screen for neonatal hyperbilirubinemia
  15. NT-proBNP levels in preeclampsia, intrauterine growth restriction as well as in the prediction on an imminent delivery
  16. Serum N-glycan fingerprint nomogram predicts liver fibrosis: a multicenter study
  17. Hematology and Coagulation
  18. Performance of digital morphology analyzer Vision Pro on white blood cell differentials
  19. Cardiovascular Diseases
  20. Prognostic implication of elevated cardiac troponin I in patients visiting emergency department without diagnosis of coronary artery disease
  21. Relationships between renal function variations and relative changes in cardiac troponin T concentrations based on quantile generalized additive models (qgam)
  22. Diabetes
  23. Association of hemoglobin H (HbH) disease with hemoglobin A1c and glycated albumin in diabetic and non-diabetic patients
  24. Comparative study of i-SENS glucometers in neonates using capillary blood samples
  25. Infectious Diseases
  26. Evaluation of four commercial, fully automated SARS-CoV-2 antibody tests suggests a revision of the Siemens SARS-CoV-2 IgG assay
  27. Vitamin-D levels and intensive care unit outcomes of a cohort of critically ill COVID-19 patients
  28. Does mid-regional pro-adrenomedullin (MR-proADM) improve the sequential organ failure assessment-score (SOFA score) for mortality-prediction in patients with acute infections? Results of a prospective observational study
  29. Letters to the Editors
  30. Global FT4 immunoassay standardization. Response to: Kratzsch J et al. Global FT4 immunoassay standardization: an expert opinion review
  31. Free-thyroxine standardization: waiting for Godot while well serving our patients today
  32. Prevalence of SARS-CoV-2 antibodies in health care personnel of two acute care hospitals in Linz, Austria
  33. Pediatric evaluation of clinical specificity and sensitivity of SARS-CoV-2 IgG and IgM serology assays
  34. Prevention and control of COVID-19 in the penitentiary of Florence
  35. Pooling for SARS-CoV-2-testing: comparison of three commercially available RT-qPCR kits in an experimental approach
  36. Very high SARS-CoV-2 load at the emergency department presentation strongly predicts the risk of admission to the intensive care unit and death
  37. Next-generation sequencing and RT-PCR to identify a 32-day SARS-CoV-2 carrier
  38. 25-Hydroxyvitamin D concentrations in COVID-19 patients hospitalized in intensive care unit during the first wave and the second wave of the pandemic
  39. Laboratory findings in a child with SARS-CoV-2 (COVID-19) multisystem inflammatory syndrome
  40. Discrepant cardiac troponin results in a young woman
  41. Response to: towards the rational utilization of SARS-CoV-2 serological tests in clinical practice
  42. Congress Abstract
  43. 12th National Scientific Congress SPML,29–31 October 2020, Online, Portugal
https://doi.org/10.1515/cclm-2020-1588
Schlagwörter für diesen Artikel
liver cirrhosis; liver fibrosis; N-glycan; nomogram; prediction

Artikel in diesem Heft

  1. Frontmatter
  2. Editorial
  3. COVID-19: which lessons have we learned?
  4. Review
  5. Global FT4 immunoassay standardization: an expert opinion review
  6. Mini Review
  7. Mechanism of bilirubin elimination in urine: insights and prospects for neonatal jaundice
  8. Opinion Paper
  9. Laboratory medicine in the COVID-19 era: six lessons for the future
  10. EFLM Paper
  11. How to meet ISO15189:2012 pre-analytical requirements in clinical laboratories? A consensus document by the EFLM WG-PRE
  12. General Clinical Chemistry and Laboratory Medicine
  13. External quality assessment of M-protein diagnostics: a realistic impression of the accuracy and precision of M-protein quantification
  14. Error simulation modeling to assess the effects of bias and precision on bilirubin measurements used to screen for neonatal hyperbilirubinemia
  15. NT-proBNP levels in preeclampsia, intrauterine growth restriction as well as in the prediction on an imminent delivery
  16. Serum N-glycan fingerprint nomogram predicts liver fibrosis: a multicenter study
  17. Hematology and Coagulation
  18. Performance of digital morphology analyzer Vision Pro on white blood cell differentials
  19. Cardiovascular Diseases
  20. Prognostic implication of elevated cardiac troponin I in patients visiting emergency department without diagnosis of coronary artery disease
  21. Relationships between renal function variations and relative changes in cardiac troponin T concentrations based on quantile generalized additive models (qgam)
  22. Diabetes
  23. Association of hemoglobin H (HbH) disease with hemoglobin A1c and glycated albumin in diabetic and non-diabetic patients
  24. Comparative study of i-SENS glucometers in neonates using capillary blood samples
  25. Infectious Diseases
  26. Evaluation of four commercial, fully automated SARS-CoV-2 antibody tests suggests a revision of the Siemens SARS-CoV-2 IgG assay
  27. Vitamin-D levels and intensive care unit outcomes of a cohort of critically ill COVID-19 patients
  28. Does mid-regional pro-adrenomedullin (MR-proADM) improve the sequential organ failure assessment-score (SOFA score) for mortality-prediction in patients with acute infections? Results of a prospective observational study
  29. Letters to the Editors
  30. Global FT4 immunoassay standardization. Response to: Kratzsch J et al. Global FT4 immunoassay standardization: an expert opinion review
  31. Free-thyroxine standardization: waiting for Godot while well serving our patients today
  32. Prevalence of SARS-CoV-2 antibodies in health care personnel of two acute care hospitals in Linz, Austria
  33. Pediatric evaluation of clinical specificity and sensitivity of SARS-CoV-2 IgG and IgM serology assays
  34. Prevention and control of COVID-19 in the penitentiary of Florence
  35. Pooling for SARS-CoV-2-testing: comparison of three commercially available RT-qPCR kits in an experimental approach
  36. Very high SARS-CoV-2 load at the emergency department presentation strongly predicts the risk of admission to the intensive care unit and death
  37. Next-generation sequencing and RT-PCR to identify a 32-day SARS-CoV-2 carrier
  38. 25-Hydroxyvitamin D concentrations in COVID-19 patients hospitalized in intensive care unit during the first wave and the second wave of the pandemic
  39. Laboratory findings in a child with SARS-CoV-2 (COVID-19) multisystem inflammatory syndrome
  40. Discrepant cardiac troponin results in a young woman
  41. Response to: towards the rational utilization of SARS-CoV-2 serological tests in clinical practice
  42. Congress Abstract
  43. 12th National Scientific Congress SPML,29–31 October 2020, Online, Portugal
Jetzt anmelden und 20% sparen
Institutioneller Zugang
Wie funktioniert Authentifizierung?
Haben Sie eine Idee, wie wir unsere Website verbessern können?
Bitte schreiben Sie uns.
© 2025 De Gruyter Brill
Heruntergeladen am 23.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/cclm-2020-1588/html
Button zum nach oben scrollen